Acute Coronary Syndrome Treatment: Introduction
Acute coronary syndrome (ACS) is associated with sudden rupture of plaque inside the coronary artery and refer to a spectrum of clinical symptoms ranging from ST-segment elevation myocardial infarction or heart attack (STEMI) to presentations found in non–ST-segment elevation myocardial infarction or heart attack (NSTEMI) or in unstable angina
Read Report Overview - https://www.transparencymarketresearch.com/acute-coronary-syndrometreatment-market.html
Acute coronary syndrome treatment market is expected to witness the launch of several new therapies, which will drive market expansion. New therapies, such as PCSK9 inhibitors Repatha (evolocumab), Praluent (alirocumab), and angiotensin receptor-neprilisin inhibitor (ARNI) Entresto (sacubitril/valsartan) would fuel market growth. Treatment of acute coronary syndrome include prehospital care (oxygen, aspirin, and nitrates), drug treatment (antiplatelet drugs, antianginal drugs, anticoagulants), and reperfusion therapy
Key Drivers and Restraints of Global Acute Coronary Syndrome Treatment Market
Increase in the number of lifestyle-related diseases such as diabetes, blood pressure, and obesity is driving market growth. According to the WHO (2014), around 1.9 billion of the adult population was obese or overweight. Hence, an increase in the incidence rate of lifestyle-related diseases is leading to cardiovascular disorder, thereby needing acute coronary syndrome treatment.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=74670
Prevalence rate of cardiovascular disorder is rising due to rapid increase in the geriatric population. The geriatric population is more vulnerable to diseases due to poor immunity. According to the WHO, the global geriatric population is expected to increase from 524 million in 2010 to 1.5 billion by 2050. This is anticipated to drive the demand for acute coronary syndrome disease treatments, which, in turn, is likely to provide opportunities for companies operating in the global acute coronary syndrome treatment market. Changing demographics in emerging economies, such as China, India, Brazil, and South Africa, are anticipated to provide high growth opportunities to pharmaceutical companies. Public and private health care expenditure in these countries is expected to increase significantly. For instance, according to the World Bank Group, in 2014, China’s health care expenditure was 5.5% of the GDP, and by 2020, the country’s health care expenditure is expected to grow two-fold. Robust growth in health care expenditure and rise in global per capita income are projected to fuel the expansion of the acute coronary syndrome treatment market. Improving health care infrastructure and government reimbursement programs in developed as well as developing countries are likely to provide growth opportunities for the acute coronary syndrome treatment market in the near future
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=74670